<?xml version='1.0' encoding='utf-8'?>
<document id="31089975"><sentence text="Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review."><entity charOffset="0-8" id="DDI-PubMed.31089975.s1.e0" text="Apixaban" /></sentence><sentence text="Apixaban is an oral, direct factor Xa inhibitor that inhibits both free and clot-bound factor Xa, and has been approved for clinical use in several thromboembolic disorders, including reduction of stroke risk in non-valvular atrial fibrillation, thromboprophylaxis following hip or knee replacement surgery, the treatment of deep vein thrombosis or pulmonary embolism, and prevention of recurrent deep vein thrombosis and pulmonary embolism"><entity charOffset="0-8" id="DDI-PubMed.31089975.s2.e0" text="Apixaban" /></sentence><sentence text=" The absolute oral bioavailability of apixaban is ~ 50%"><entity charOffset="38-46" id="DDI-PubMed.31089975.s3.e0" text="apixaban" /></sentence><sentence text=" Food does not have a clinically meaningful impact on the bioavailability" /><sentence text=" Apixaban exposure increases dose proportionally for oral doses up to 10 mg"><entity charOffset="1-9" id="DDI-PubMed.31089975.s5.e0" text="Apixaban" /></sentence><sentence text=" Apixaban is rapidly absorbed, with maximum concentration occurring 3-4 h after oral administration, and has a half-life of approximately 12 h"><entity charOffset="1-9" id="DDI-PubMed.31089975.s6.e0" text="Apixaban" /></sentence><sentence text=" Elimination occurs via multiple pathways including metabolism, biliary excretion, and direct intestinal excretion, with approximately 27% of total apixaban clearance occurring via renal excretion"><entity charOffset="148-156" id="DDI-PubMed.31089975.s7.e0" text="apixaban" /></sentence><sentence text=" The pharmacokinetics of apixaban are consistent across a broad range of patients, and apixaban has limited clinically relevant interactions with most commonly prescribed medications, allowing for fixed dosages without the need for therapeutic drug monitoring"><entity charOffset="25-33" id="DDI-PubMed.31089975.s8.e0" text="apixaban" /><entity charOffset="87-95" id="DDI-PubMed.31089975.s8.e1" text="apixaban" /><pair ddi="false" e1="DDI-PubMed.31089975.s8.e0" e2="DDI-PubMed.31089975.s8.e0" /><pair ddi="false" e1="DDI-PubMed.31089975.s8.e0" e2="DDI-PubMed.31089975.s8.e1" /></sentence><sentence text=" The pharmacodynamic effect of apixaban is closely correlated with apixaban plasma concentration"><entity charOffset="31-39" id="DDI-PubMed.31089975.s9.e0" text="apixaban" /><entity charOffset="67-75" id="DDI-PubMed.31089975.s9.e1" text="apixaban" /><pair ddi="false" e1="DDI-PubMed.31089975.s9.e0" e2="DDI-PubMed.31089975.s9.e0" /><pair ddi="false" e1="DDI-PubMed.31089975.s9.e0" e2="DDI-PubMed.31089975.s9.e1" /></sentence><sentence text=" This review provides a summary of the pharmacokinetic, pharmacodynamic, biopharmaceutical, and drug-drug interaction profiles of apixaban"><entity charOffset="130-138" id="DDI-PubMed.31089975.s10.e0" text="apixaban" /></sentence><sentence text=" Additionally, the population-pharmacokinetic analyses of apixaban in both healthy subjects and in the target patient populations are discussed"><entity charOffset="58-66" id="DDI-PubMed.31089975.s11.e0" text="apixaban" /></sentence><sentence text="" /></document>